Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity

Role of 5-HT1B/1D and 5-HT2 receptors

Michael G. Bankson, Kathryn Cunningham

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The role of serotonin 5-HT2 receptors (5-HT2R) in the hyperactivity induced by (+)-3,4-methylenedioxy-methamphetamine ((+)-MDMA; 3 mg/kg) was investigated. Hyperactivity induced by (+)-MDMA was robustly potentiated by the 5-HT2B/2CR antagonist SB 206553 (1.0, 2.0, and 4.0 mg/kg). Administration of the 5-HT1B/1DR antagonist GR 127935 (2.5 mg/kg) or the 5-HT2AR antagonist M100907 (1.0 mg/kg) partially suppressed the potentiated hyperactivity seen following SB 206553 plus (+)-MDMA; a blockade to activity levels seen with (+)-MDMA alone was observed following the combination of GR 127935 plus M100907. A modest potentiative interaction was seen when SB 206553 was combined with the DA releaser amphetamine (0.5 mg/kg) or amphetamine plus the 5-HT releaser fenfluramine (4.0 mg/kg). SB 206553 (1-4 mg/kg), GR 127935 (2.5 mg/kg) and M100907 (1 mg/kg) did not alter spontaneous activity upon administration singly or in combination. These data suggest that activation of 5-HT2CR exerts a strong inhibitory influence on the hyperactivity induced by (+)-MDMA, and that 5-HT2CR blockade unmasks hyperactivity mediated through several mechanisms.

Original languageEnglish (US)
Pages (from-to)40-52
Number of pages13
JournalNeuropsychopharmacology
Volume26
Issue number1
DOIs
StatePublished - 2002

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Locomotion
Pharmacology
Amphetamine
Serotonin 5-HT2 Receptors
Serotonin 5-HT1 Receptor Antagonists
Serotonin 5-HT2 Receptor Antagonists
Fenfluramine
Methamphetamine
Serotonin
SB 206553
GR 127935
MDL 100907

Keywords

  • 3,4-Methylenedioxymethamphetamine
  • 5-HT receptors
  • 5-HT receptors
  • 5-HT receptors
  • M100907
  • MDL 100907
  • MDMA
  • SB 206553
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{36278e6a66a644b7a10dd38b4e3228cd,
title = "Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: Role of 5-HT1B/1D and 5-HT2 receptors",
abstract = "The role of serotonin 5-HT2 receptors (5-HT2R) in the hyperactivity induced by (+)-3,4-methylenedioxy-methamphetamine ((+)-MDMA; 3 mg/kg) was investigated. Hyperactivity induced by (+)-MDMA was robustly potentiated by the 5-HT2B/2CR antagonist SB 206553 (1.0, 2.0, and 4.0 mg/kg). Administration of the 5-HT1B/1DR antagonist GR 127935 (2.5 mg/kg) or the 5-HT2AR antagonist M100907 (1.0 mg/kg) partially suppressed the potentiated hyperactivity seen following SB 206553 plus (+)-MDMA; a blockade to activity levels seen with (+)-MDMA alone was observed following the combination of GR 127935 plus M100907. A modest potentiative interaction was seen when SB 206553 was combined with the DA releaser amphetamine (0.5 mg/kg) or amphetamine plus the 5-HT releaser fenfluramine (4.0 mg/kg). SB 206553 (1-4 mg/kg), GR 127935 (2.5 mg/kg) and M100907 (1 mg/kg) did not alter spontaneous activity upon administration singly or in combination. These data suggest that activation of 5-HT2CR exerts a strong inhibitory influence on the hyperactivity induced by (+)-MDMA, and that 5-HT2CR blockade unmasks hyperactivity mediated through several mechanisms.",
keywords = "3,4-Methylenedioxymethamphetamine, 5-HT receptors, 5-HT receptors, 5-HT receptors, M100907, MDL 100907, MDMA, SB 206553, Serotonin",
author = "Bankson, {Michael G.} and Kathryn Cunningham",
year = "2002",
doi = "10.1016/S0893-133X(01)00345-1",
language = "English (US)",
volume = "26",
pages = "40--52",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity

T2 - Role of 5-HT1B/1D and 5-HT2 receptors

AU - Bankson, Michael G.

AU - Cunningham, Kathryn

PY - 2002

Y1 - 2002

N2 - The role of serotonin 5-HT2 receptors (5-HT2R) in the hyperactivity induced by (+)-3,4-methylenedioxy-methamphetamine ((+)-MDMA; 3 mg/kg) was investigated. Hyperactivity induced by (+)-MDMA was robustly potentiated by the 5-HT2B/2CR antagonist SB 206553 (1.0, 2.0, and 4.0 mg/kg). Administration of the 5-HT1B/1DR antagonist GR 127935 (2.5 mg/kg) or the 5-HT2AR antagonist M100907 (1.0 mg/kg) partially suppressed the potentiated hyperactivity seen following SB 206553 plus (+)-MDMA; a blockade to activity levels seen with (+)-MDMA alone was observed following the combination of GR 127935 plus M100907. A modest potentiative interaction was seen when SB 206553 was combined with the DA releaser amphetamine (0.5 mg/kg) or amphetamine plus the 5-HT releaser fenfluramine (4.0 mg/kg). SB 206553 (1-4 mg/kg), GR 127935 (2.5 mg/kg) and M100907 (1 mg/kg) did not alter spontaneous activity upon administration singly or in combination. These data suggest that activation of 5-HT2CR exerts a strong inhibitory influence on the hyperactivity induced by (+)-MDMA, and that 5-HT2CR blockade unmasks hyperactivity mediated through several mechanisms.

AB - The role of serotonin 5-HT2 receptors (5-HT2R) in the hyperactivity induced by (+)-3,4-methylenedioxy-methamphetamine ((+)-MDMA; 3 mg/kg) was investigated. Hyperactivity induced by (+)-MDMA was robustly potentiated by the 5-HT2B/2CR antagonist SB 206553 (1.0, 2.0, and 4.0 mg/kg). Administration of the 5-HT1B/1DR antagonist GR 127935 (2.5 mg/kg) or the 5-HT2AR antagonist M100907 (1.0 mg/kg) partially suppressed the potentiated hyperactivity seen following SB 206553 plus (+)-MDMA; a blockade to activity levels seen with (+)-MDMA alone was observed following the combination of GR 127935 plus M100907. A modest potentiative interaction was seen when SB 206553 was combined with the DA releaser amphetamine (0.5 mg/kg) or amphetamine plus the 5-HT releaser fenfluramine (4.0 mg/kg). SB 206553 (1-4 mg/kg), GR 127935 (2.5 mg/kg) and M100907 (1 mg/kg) did not alter spontaneous activity upon administration singly or in combination. These data suggest that activation of 5-HT2CR exerts a strong inhibitory influence on the hyperactivity induced by (+)-MDMA, and that 5-HT2CR blockade unmasks hyperactivity mediated through several mechanisms.

KW - 3,4-Methylenedioxymethamphetamine

KW - 5-HT receptors

KW - 5-HT receptors

KW - 5-HT receptors

KW - M100907

KW - MDL 100907

KW - MDMA

KW - SB 206553

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0036147215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147215&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(01)00345-1

DO - 10.1016/S0893-133X(01)00345-1

M3 - Article

VL - 26

SP - 40

EP - 52

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -